InspireMD (NYSE:NSPR) is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.
The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets. CGuard EPS combines a self-expanding nitinol stent with an ultrathin polyethylene terephthalate (PET) MicroNet mesh, designed to trap plaque fragments and reduce the risk of peri-procedural stroke. Clinical data have demonstrated promising rates of procedural success and low incidence of embolic complications, positioning CGuard EPS as a leading choice for interventionalists in Europe, Latin America, and parts of Asia Pacific.
InspireMD was founded in 2002 and has since established a presence in key global markets outside the United States, while continuing to pursue regulatory clearance from the U.S. Food and Drug Administration. The company maintains headquarters in Tel Aviv, Israel, with additional offices in the United States to support clinical and regulatory activities. InspireMD collaborates with hospitals, research institutions, and distributors worldwide to broaden access to its stent systems and to advance the clinical evidence base for its technology.
The company is guided by a management team with seasoned expertise in interventional cardiology, neurology, regulatory affairs and medical device commercialization. InspireMD remains committed to innovation in vascular therapy and continues to invest in product development, clinical research and strategic partnerships to address unmet needs in the treatment of atherosclerotic and neurovascular diseases.
